STERIS plc (Ireland)
STE
Positions held
Your positionsSTE isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- STERIS plc operates in the medical devices industry, which is experiencing robust growth driven by increasing healthcare demands and technological advancements.
- In 2026, STERIS reported a revenue of $5.94 billion, reflecting a 8.7% increase from $5.46 billion in 2025.
- The company achieved a net income of $782.3 million in 2026, up from $614.7 million in 2025, indicating strong earnings growth.
- STERIS plc faces significant competition in the medical devices sector, which may pressure margins and market share.
- The quarterly revenue decreased by 6% from $1.6 billion in Q1 2026 to $1.5 billion in Q2 2026.
- The company's stock has a 'Strong Sell' signal with a score of -17.00, indicating bearish market sentiment.
Fundamentals
| Market cap | $20.55B | Enterprise value | $22.13B | Trailing P/E | 25.77 | Forward P/E | 17.21 |
| PEG | 1.75 | Price / book | 2.85 | Beta | 0.93 | Dividend yield | 1.22% |
| Revenue growth | 7.3% | Earnings growth | 14.0% | Gross margin | 44.4% | Operating margin | 19.2% |
| Profit margin | 13.3% | ROE | 11.4% | ROA | 6.8% | Debt / equity | 0.28 |
| Current ratio | 1.91 | Free cash flow | $798.86M | Analyst recommendation | buy | Mean target | $263.13 |
| 52w high | $269.44 | 52w low | $195.14 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.5B | $1.6B | $1.5B | $1.5B | $1.4B | — |
| Op margin | 19.2% | 19.9% | 18.3% | 18.4% | 17.8% | — |
| Net income | $200M | $220M | $193M | $192M | $177M | — |
| Gross margin | 45.8% | 43.9% | 43.8% | 44.2% | 45.1% | — |
| Gross profit | $684M | $697M | $656M | $646M | $628M | — |
| Operating income | $286M | $317M | $274M | $268M | $248M | — |
- Revenue -6% vs prior quarter ($1.5B vs $1.6B).
- Gross margin 45.8% (was 43.9% prior quarter).
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $5.9B | $5.5B | $5.1B | $4.5B | — |
| Op margin | 18.6% | 17.6% | 16.8% | 17.5% | — |
| Net income | $782M | $615M | $378M | $107M | — |
| Gross margin | 44.2% | 44.0% | 43.2% | 43.7% | — |
| Gross profit | $2.6B | $2.4B | $2.2B | $2.0B | — |
| Operating income | $1.1B | $961M | $862M | $792M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-28 · 3 Healthcare Stocks That Fall Short
2026-09-22 · 3 Mid-Cap Stocks with Open Questions
2026-09-18 · 1 of Wall Street’s Favorite Stocks with Exciting Potential and 2 We Brush Off
2026-09-16 · STERIS Stock: Is STE Underperforming the Healthcare Sector?
2026-09-04 · Steris (STE) Down 2.1% Since Last Earnings Report: Can It Rebound?
2026-09-03 · STERIS (STE) Stock Looks Reasonable On Earnings With Cash Flow Slightly Stretched
2026-09-02 · STERIS (STE) Could Be 12% Below Fair Value As Conference Focus Returns
2026-09-01 · STERIS to Present at the Morgan Stanley Healthcare Conference
2026-08-26 · STERIS Stock Outlook: Is Wall Street Bullish or Bearish?
2026-08-21 · Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?
2026-08-20 · Should Investors Buy STERIS as Growth Meets Reasonable Valuation?
2026-08-19 · 3 Reasons STE is Risky and 1 Stock to Buy Instead
Price (daily)
Full chart · RSI · MACD · patterns